COVID - 19, Hearing, Ototoxicity
Conditions
Brief summary
Investigation of the Impact of Medications Used in COVID-19 Treatment and COVID-19 Vaccine on Hearing
Detailed description
This study aims to investigate the impact of medications containing the active ingredients hydroxychloroquine and favipiravir on the auditory system, as well as to examine the effect of COVID-19 on hearing and its potential relationship with medication use and COVID-19 vaccine dose.
Interventions
DIAGNOSTIC_TESTHearing tests
Participants' pure tone thresholds, high frequency thresholds, and otoacoustic emissions measurements were evaluated.
Sponsors
Zonguldak Bulent Ecevit University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
Age between 18 and 35 For the Medication group: Having had COVID-19 and using COVID-19 medications For the Non-Medication group: Having had COVID-19 and not using COVID-19 medications For the Control group: Having never had COVID-19
Exclusion criteria
Previously diagnosed with hearing loss Use of ototoxic medications other than those specified Pathology detected during tympanometric evaluation or otoscopic examination Chronic disease Family history of hearing loss History of meningitis Neurological disorders Acute or chronic ear infection Admission to intensive care
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pure tone and high frequency hearing thresholds | December, 2021-February 2022 |
| Transient evoked otoacoustic emissions - Signal/noise ratio | December, 2021-February 2022 |
| Distortion product otoacoustic emissions- signal/noise ratio | December, 2021-February 2022 |
Countries
Turkey (Türkiye)
Outcome results
None listed